Physician profile
Pushkar M Kanade
NPI 1144506445
$31,494.51
in general payments reported to CMS, 2019-2025
21 companies · $5,316 in 2025
The $5,316 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $278 · 2022: $210 · 2023: $10K · 2024: $16K · 2025: $5,316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Honoraria: $8,575 · Travel and Lodging: $3,705 · Consulting Fee: $3,600 · Food and Beverage: $1,872 · Education: $4.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,250.00 |
| Honoraria | $8,575.00 |
| Travel and Lodging | $3,704.79 |
| Consulting Fee | $3,600.00 |
| Food and Beverage | $1,872.21 |
| Education | $4.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $10,658.64 | 2022-2025 | Krystexxa, Tavneos |
| Ardelyx, INC. | $9,915.70 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Horizon Therapeutics Plc | $9,815.47 | 2022-2023 | Krystexxa |
| Fresenius USA Marketing, INC. | $211.46 | 2021-2025 | Velphoro, Velphoro |
| Travere Therapeutics, INC. | $196.09 | 2022-2025 | Filspari |
| Otsuka America Pharmaceutical, INC. | $195.31 | 2021 | |
| Mallinckrodt Hospital Products INC. | $135.98 | 2023-2024 | Acthar |
| Aurinia Pharma U.S., INC. | $101.32 | 2022-2023 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $65.08 | 2021-2023 | Farxiga |
| Alexion Pharmaceuticals, INC. | $39.61 | 2024 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $37.63 | 2023-2024 | |
| Calliditas Therapeutics US INC. | $33.56 | 2023-2025 | Tarpeyo |
| Vifor Pharma, INC. | $28.98 | 2021 | |
| Scpharmaceuticals INC. | $24.52 | 2024 | |
| Daiichi Sankyo INC. | $20.42 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $14.74 | 2025 | Purified Cortrophin Gel |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pushkar Kanade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.